These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8103687)

  • 1. Cyclosporin in psoriasis: pathophysiology and experimental data.
    Mozzanica N; Pigatto PD; Finzi AF
    Dermatology; 1993; 187 Suppl 1():3-7. PubMed ID: 8103687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanisms of action of cyclosporin A in the treatment of psoriasis.
    Wong RL; Winslow CM; Cooper KD
    Immunol Today; 1993 Feb; 14(2):69-74. PubMed ID: 8447934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study.
    Finzi AF; Mozzanica N; Cattaneo A; Chiappino G; Pigatto PD
    J Am Acad Dermatol; 1989 Jul; 21(1):91-7. PubMed ID: 2787338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A.
    Gupta AK; Baadsgaard O; Ellis CN; Voorhees JJ; Cooper KD
    Arch Dermatol Res; 1989; 281(4):219-26. PubMed ID: 2673064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Concepts of the mechanisms of action of cyclosporin in psoriasis. A review with guidelines on therapy].
    Mrowietz U
    Hautarzt; 1993 Jun; 44(6):353-60. PubMed ID: 8392987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy.
    Servitje O; Bordas X; Serón D; Vidaller A; Moreno A; Curcó N; Sais G; Peyrí J
    J Cutan Pathol; 1996 Oct; 23(5):431-6. PubMed ID: 8915851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective.
    Griffiths CE; Voorhees JJ
    J Invest Dermatol; 1990 Nov; 95(5 Suppl):53S-55S. PubMed ID: 16788634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etretinate therapy reduces polymorphonuclear leukocyte chemotaxis--enhancing properties of psoriatic serum.
    Ellis CN; Kang S; Grekin RC; Voorhees JJ; Silva J
    J Am Acad Dermatol; 1985 Sep; 13(3):437-43. PubMed ID: 4056118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil chemotaxis in psoriasis.
    Wahba A; Cohen H; Bar-Eli M; Callily R
    Acta Derm Venereol; 1979; 59(5):441-5. PubMed ID: 93368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil chemotaxis in psoriasis before and after PUVA therapy.
    Guillot B; Guilhou JJ; Vendrel JP; Meynadier J
    Arch Dermatol Res; 1983; 275(1):19-22. PubMed ID: 6847241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients.
    Rentenaar RJ; Heydendael VM; van Diepen FN; de Rie MA; ten Berge IJ
    J Clin Immunol; 2004 Jul; 24(4):361-9. PubMed ID: 15163892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quantitative changes in CD4+ and CD8+ T-lymphocytes in the skin of patients with psoriasis treated with cyclosporin A].
    Adamicová K; Fetisovová Z; Cingel P; Péc J; Parobeková K; Chromej I
    Cesk Patol; 2001 Nov; 37(4):154-7. PubMed ID: 11813632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of zinc therapy on neutrophil chemotaxis in psoriasis.
    Leibovici V; Statter M; Weinrauch L; Tzfoni E; Matzner Y
    Isr J Med Sci; 1990 Jun; 26(6):306-9. PubMed ID: 2380030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The enhanced monocyte and neutrophil chemotaxis in psoriasis is normalized after treatment with psoralens plus ultraviolet A and anthralin.
    Ternowitz T
    J Am Acad Dermatol; 1987 Jun; 16(6):1169-75. PubMed ID: 3597858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine A inhibits polymorphonuclear leukocyte chemotaxis in vivo.
    Pigatto PD; Mozzanica N; Polenghi MM; Altomare GF; Finzi AF
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):91-4. PubMed ID: 3381307
    [No Abstract]   [Full Text] [Related]  

  • 16. Intralesional cyclosporin in psoriasis: effects on T lymphocyte and dendritic cell subpopulations.
    Baker BS; Powles AV; Savage CR; McFadden JP; Valdimarsson H; Fry L
    Br J Dermatol; 1989 Feb; 120(2):207-13. PubMed ID: 2784322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporin A and vitamin D metabolism: studies in patients with psoriasis and in rats.
    Shaw AJ; Hayes ME; Davies M; Edwards BD; Ballardie FW; Chalmers RJ; Mawer EB
    Clin Sci (Lond); 1994 May; 86(5):627-32. PubMed ID: 8033516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in numbers of epidermal cell adhesion molecules caused by oral cyclosporin in psoriasis.
    Edwards BD; Andrew SM; O'Driscoll JB; Chalmers RJ; Ballardie FW; Freemont AJ
    J Clin Pathol; 1993 Aug; 46(8):713-7. PubMed ID: 7691894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokinetic and chemotactic factors in psoriasis scale extracts.
    Dahl MV; Lindroos WE; Nelson RD
    J Invest Dermatol; 1978 Dec; 71(6):402-6. PubMed ID: 722120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cyclosporine on immunologic mechanisms in psoriasis.
    Cooper KD; Voorhees JJ; Fisher GJ; Chan LS; Gupta AK; Baadsgaard O
    J Am Acad Dermatol; 1990 Dec; 23(6 Pt 2):1318-26; discussion 1326-8. PubMed ID: 2277141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.